Vasopressors may have differing immune effects in septic shock

Septic shock can involve both excessive inflammation and immune suppression. This review examines how vasopressors used to support circulation may also affect immune function, proposing a spectrum of effects rather than treating these drugs as immunologically equivalent. The evidence discussed includes laboratory and animal studies, human endotoxin experiments, and clinical observations; it is not a comparative clinical trial of vasopressor strategies.

Catecholamines, including norepinephrine, have been associated with reduced pro-inflammatory cytokine release, reactive oxygen species production, and phagocytosis, alongside increased interleukin-10. In an observational cohort of 195 patients with septic shock, higher norepinephrine doses correlated with a lower blood TNF/IL-10 ratio. By contrast, vasopressin had few direct immune effects in experimental models. Angiotensin II enhanced bacterial clearance and immune-cell activity in mice, although its effects on cytokines appeared to vary over time.

The authors emphasize that these findings are predominantly experimental or indirect and do not establish that changing vasopressor choice improves patient outcomes. Immune effects may differ by cell type, infection, and timing, and both immune suppression and augmentation could help or harm. The proposed framework is a rationale for prospective studies, not a basis for tailoring current vasopressor selection to immune phenotype.